THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 91 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2014. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,832,168 | -32.2% | 328,177 | -18.7% | 0.00% | 0.0% |
Q2 2023 | $4,175,801 | -20.3% | 403,459 | -16.4% | 0.00% | -50.0% |
Q1 2023 | $5,239,161 | -9.6% | 482,872 | -6.5% | 0.00% | 0.0% |
Q4 2022 | $5,793,873 | +8.8% | 516,388 | -1.6% | 0.00% | 0.0% |
Q3 2022 | $5,323,000 | +16.7% | 524,916 | +4.3% | 0.00% | 0.0% |
Q2 2022 | $4,562,000 | +18.5% | 503,477 | +25.0% | 0.00% | +100.0% |
Q1 2022 | $3,850,000 | -10.8% | 402,640 | +3.1% | 0.00% | 0.0% |
Q4 2021 | $4,316,000 | +65.7% | 390,545 | +11.0% | 0.00% | 0.0% |
Q3 2021 | $2,604,000 | -49.7% | 351,793 | -1.3% | 0.00% | -50.0% |
Q2 2021 | $5,178,000 | -23.9% | 356,544 | +6.9% | 0.00% | 0.0% |
Q1 2021 | $6,807,000 | +18.4% | 333,484 | +3.1% | 0.00% | 0.0% |
Q4 2020 | $5,750,000 | +24.0% | 323,578 | +3.2% | 0.00% | 0.0% |
Q3 2020 | $4,637,000 | -29.7% | 313,564 | -0.2% | 0.00% | -33.3% |
Q2 2020 | $6,596,000 | -4.7% | 314,210 | +4.9% | 0.00% | -25.0% |
Q1 2020 | $6,924,000 | -0.3% | 299,576 | +11.7% | 0.00% | 0.0% |
Q4 2019 | $6,942,000 | +37.7% | 268,100 | +3.6% | 0.00% | +33.3% |
Q3 2019 | $5,043,000 | +22.5% | 258,863 | +2.7% | 0.00% | 0.0% |
Q2 2019 | $4,116,000 | -24.0% | 251,994 | +5.5% | 0.00% | 0.0% |
Q1 2019 | $5,418,000 | -9.9% | 238,952 | +1.7% | 0.00% | -40.0% |
Q4 2018 | $6,011,000 | -22.3% | 234,882 | -0.8% | 0.01% | 0.0% |
Q3 2018 | $7,739,000 | +50.8% | 236,860 | +4.7% | 0.01% | +25.0% |
Q2 2018 | $5,132,000 | +1.2% | 226,268 | +8.2% | 0.00% | 0.0% |
Q1 2018 | $5,071,000 | -8.9% | 209,075 | +4.7% | 0.00% | 0.0% |
Q4 2017 | $5,569,000 | -15.1% | 199,677 | +4.2% | 0.00% | -33.3% |
Q3 2017 | $6,559,000 | -7.2% | 191,558 | +8.0% | 0.01% | -14.3% |
Q2 2017 | $7,065,000 | +18.0% | 177,317 | +9.0% | 0.01% | +16.7% |
Q1 2017 | $5,988,000 | +29.1% | 162,608 | +11.8% | 0.01% | +20.0% |
Q4 2016 | $4,638,000 | +7.2% | 145,472 | +21.9% | 0.01% | 0.0% |
Q3 2016 | $4,327,000 | +67.8% | 119,384 | +5.0% | 0.01% | +66.7% |
Q2 2016 | $2,579,000 | +63.0% | 113,650 | +35.1% | 0.00% | +50.0% |
Q1 2016 | $1,582,000 | +8.1% | 84,138 | -5.8% | 0.00% | 0.0% |
Q4 2015 | $1,464,000 | +79.9% | 89,274 | +20.6% | 0.00% | +100.0% |
Q3 2015 | $814,000 | -9.7% | 74,016 | +7.0% | 0.00% | 0.0% |
Q2 2015 | $901,000 | -22.6% | 69,193 | +3.2% | 0.00% | -50.0% |
Q1 2015 | $1,164,000 | +22.0% | 67,041 | +4.9% | 0.00% | +100.0% |
Q4 2014 | $954,000 | -33.0% | 63,879 | +3.5% | 0.00% | -50.0% |
Q3 2014 | $1,424,000 | -26.1% | 61,746 | +2.3% | 0.00% | -33.3% |
Q2 2014 | $1,926,000 | – | 60,385 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |